<DOC>
	<DOCNO>NCT00397423</DOCNO>
	<brief_summary>This study examine effectiveness G-CSF treating patient amyotrophic lateral sclerosis ( ALS ) - fatal neurological degenerative disease cause adult-onset , progressive motor neuron loss spinal cord , brain stem motor cortex . Patients develop progressive wasting weakness upper low limb , bulbar respiratory muscle . Usually death respiratory failure typically within 3-5 year diagnosis . Although various treatment ALS , riluzole approve treatment delay disease progression . G-CSF approve drug use increase white blood cell count . Moreover , G-CSF receptor express neuron . It act anti-apoptosis activate several protective pathway , stimulate neuronal differentiation adult neural stem cell brain , improve long-term recovery . G-CSF novel neurotrophic factor , highly attractive candidate treatment neurodegenerative condition ALS . Patients 18 65 year age mild moderately severe ALS 0.5 2 year duration may eligible study . Candidates screen medical history possible review medical record , physical examination , blood test , urine stool analysis , electrocardiogram , electrophysiological examination , neurological imaging , woman , pregnancy test . Participants drug therapy accord randomized number . One group receive G-CSF group receive placebo . All participant receive riluzole treatment . For procedure , patient give medication lessen anxiety discomfort . Patients receive drug injection every 3 month 5 day . The G-CSF dosage 5Î¼g/kg/day . Physical examination interview , Appel ALS scale ALS-Functional Rating Scale do 14 , 28 day 3 , 6 , 9 , 12 month . Electrophysiological examination test per 3 month . Blood sample collect treat 5 , 14 , 28 day 3 , 6 , 9 , 12 month .</brief_summary>
	<brief_title>G-CSF Treatment Amyotrophic Lateral Sclerosis : A RCT Study Assessing Clinical Response</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>All subject must verifiable diagnosis ALS 0.5 2 year ' duration . The diagnosis must support Revised Criteria World Federation Neurology . The grades diagnosis must clinically definite ALS clinically probable ALS . All subject must age 18 65 . The ALS mildly moderate base ALS Health State Scale . Electrophysiological feature show CMAP amplitude motor nerve normal mild decline . Serum creatine kinase normal mild upper , less 500U/L . If anyone eligibility requirement meet Use investigational agent within 30 day begin treatment phase study Severe cardiac , pulmonary , hepatic or/and hematic disease HIV positivity sign symptoms consistent HIV infection Pregnant nursing woman History cancer le 5 year documentation diseasefree state History anaphylactic reaction hypersensitivity GCSF proteins derive E.coli Alcohol drug abuse recent 1 year Ca n't understand obey rule treatment Blood donor recent 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Granulocyte Colony Stimulating Factor</keyword>
	<keyword>Randomized Control Trial Study</keyword>
</DOC>